Scholarlink

Background <p>This study investigated the correlation between glucose time-in-range (TIR) and hepatic steatosis severity or liver fibrosis risk in Chinese adults with type 2 diabetes mellitus (T2DM) comorbid with metabolic dysfunction-associated steatotic liver disease (MASLD).</p> Methods <p>Participants with T2DM were evaluated for hepatic steatosis and fibrosis using vibration-controlled transient elastography. TIR was calculated based on data from a retrospective continuous glucose monitoring system.</p> Results <p>A total of 184 T2DM patients with MASLD were enrolled. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) decreased with increasing TIR (<i>p</i> &lt; 0.05). Spearman correlation showed negative correlations between CAP, LSM, and TIR (<i>r</i> = -0.824 and − 0.842, <i>p</i> &lt; 0.05) and positive correlations with basal insulin resistance (HOMA-IR) (<i>r</i> = 0.205 and 0.208, <i>p</i> &lt; 0.01). Multiple linear regression revealed TIR and HOMA-IR independently correlated with CAP (std. regression coefficients = -0.695 and 0.103, <i>p</i> &lt; 0.05) and LSM (std. regression coefficients = -0.735 and 0.083, <i>p</i> &lt; 0.05), wit0.34&#xa0;h TIR having a stronger impact. Binary logistic regression showed TIR Groups 3 (70% ≥ TIR &lt; 85%) and 4 (TIR ≥ 85%) were protective for MASLD (OR = 0.26 and 0.11, 95% CI 0.10–0.66 and 0.04–0.29, <i>P</i> = 0.005 and &lt; 0.001) and liver fibrosis (OR = 0.29 and 0.13, 95% CI 0.12–0.74 and 0.05–0.36, <i>P</i> = 0.010 and &lt; 0.001) compared to TIR Group 1 (lowest quartile).</p> Conclusion <p>In T2DM patients with coexisting MASLD, a significant and independent association existed between TIR and the severity of hepatic steatosis.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月23日

查看全文
  • Chun-Hua Wang,
  • Xuan-Yao Ji,
  • Nian Ji,
  • Qing-Feng Yan,
  • Hong-Qing Xu,
  • Xue-Qin Wang,
  • Xiang-Fan Chen,
  • Chun-Feng Lu

摘要

Background

This study investigated the correlation between glucose time-in-range (TIR) and hepatic steatosis severity or liver fibrosis risk in Chinese adults with type 2 diabetes mellitus (T2DM) comorbid with metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods

Participants with T2DM were evaluated for hepatic steatosis and fibrosis using vibration-controlled transient elastography. TIR was calculated based on data from a retrospective continuous glucose monitoring system.

Results

A total of 184 T2DM patients with MASLD were enrolled. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) decreased with increasing TIR (p < 0.05). Spearman correlation showed negative correlations between CAP, LSM, and TIR (r = -0.824 and − 0.842, p < 0.05) and positive correlations with basal insulin resistance (HOMA-IR) (r = 0.205 and 0.208, p < 0.01). Multiple linear regression revealed TIR and HOMA-IR independently correlated with CAP (std. regression coefficients = -0.695 and 0.103, p < 0.05) and LSM (std. regression coefficients = -0.735 and 0.083, p < 0.05), wit0.34 h TIR having a stronger impact. Binary logistic regression showed TIR Groups 3 (70% ≥ TIR < 85%) and 4 (TIR ≥ 85%) were protective for MASLD (OR = 0.26 and 0.11, 95% CI 0.10–0.66 and 0.04–0.29, P = 0.005 and < 0.001) and liver fibrosis (OR = 0.29 and 0.13, 95% CI 0.12–0.74 and 0.05–0.36, P = 0.010 and < 0.001) compared to TIR Group 1 (lowest quartile).

Conclusion

In T2DM patients with coexisting MASLD, a significant and independent association existed between TIR and the severity of hepatic steatosis.

Clinical trial number

Not applicable.